Work

An Improved Benefit‐risk Profile of Duvelisib in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Received 2 or More Prior Therapies

Year: 2019

Type: article

Source: Hematological Oncology

DOI: 10.1002/hon.29_2630

Authors: I.W. Flinn, M.S. Davids, P. Hillmen, M. Montillo, J. Delgado, B.J. Kuss, C.S. Tam, U. Jäger, P. Ghia, S. Stilgenbauer, S. Lustgarten, D.T. Weaver, H. Youssoufian, F. Cymbalista

Institutions: Sarah Cannon, Dana-Farber Cancer Institute, St James's University Hospital, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Hospital Clínic de Barcelona, Flinders University, Flinders Medical Centre, The University of Melbourne, Peter MacCallum Cancer Centre, St Vincent's Hospital Melbourne, Medical University of Vienna, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, University Hospital Ulm, Verastem (United States), Hôpital Avicenne, Laboratoire d'hématologie

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2951349998

FWCI: 0.136

Cites:

Cited by: 1

Related to: 10